Owkin IPO
Owkin develops AI and federated learning solutions for drug discovery and development, enabling pharmaceutical companies to collaborate on research while maintaining data privacy. The company partners with major pharma companies and research institutions to accelerate medical research. Investors are interested in its unique approach to collaborative AI in healthcare and drug development.
What We Know
Owkin has not announced any plans for an initial public offering and remains a private company. The French AI company has raised significant funding, including a Series B round that reportedly valued the company at over $800 million. While Owkin's partnerships with major pharmaceutical companies and its position in AI-driven drug discovery could make it an attractive IPO candidate, no concrete plans or timeline have been announced. The company appears focused on expanding its federated learning platform and pharmaceutical partnerships rather than preparing for public markets.
Frequently Asked Questions
Has Owkin had an IPO?
No, Owkin has not had an IPO and is currently a private company. The company has not announced any plans to go public.
When is the Owkin IPO date?
Owkin has not announced an IPO date or timeline for going public. There are no confirmed details about when an IPO might occur. Sign up for alerts to stay informed.
How can I buy Owkin stock?
Owkin stock is not available for public purchase as the company remains private. Shares are only accessible to qualified investors through private investment rounds. Sign up for alerts to stay informed.
Stay Updated on the Owkin IPO
Get real-time alerts when Owkin files for an IPO, prices shares, or begins trading.
Get IPO Alerts